Skip to main navigation
Skip to search
Skip to main content
Technical University of Munich Home
Help & FAQ
English
Deutsch
Home
Profiles
Research units
Projects
Research output
Equipment
Prizes
Activities
Press/Media
Search by expertise, name or affiliation
Is there an anti-androgen withdrawal syndrome for enzalutamide?
Christoph A.J. von Klot
, Mario W. Kramer
, Alena Böker
, Thomas R.W. Herrmann
, Inga Peters
, Markus A. Kuczyk
, Uwe Ligges
,
Jürgen E. Gschwend
,
Margitta Retz
, Sebastian C. Schmid
, Arnulf Stenzl
, Christian Schwentner
, Tilmann Todenhöfer
, Michael Stöckle
, Carsten Henning Ohlmann
, Ines Azone
, René Mager
, Georg Bartsch
, Axel Haferkamp
, Axel Heidenreich
Charlotte Piper, Axel S. Merseburger
Show 2 others
Show less
Chair of Urology
Department of Urology
Hannover Medical School
pro3dure medical GmbH
Technical University of Munich
University of Tübingen
Saarland University Medical Center
Johann Wolfgang Goethe University
RWTH Aachen University
Research output
:
Contribution to journal
›
Article
›
peer-review
13
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Is there an anti-androgen withdrawal syndrome for enzalutamide?'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Enzalutamide
100%
Antiandrogen Withdrawal Syndrome
100%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
22%
Prostate-specific Antigen
22%
Anti-androgen Therapy
22%
Withdrawal Syndrome
22%
Germany
11%
Therapeutic Potential
11%
Statistical Evaluation
11%
Mechanism of Action
11%
Clinical Role
11%
Software Version
11%
Oral Administration
11%
New Therapeutics
11%
Taxane-based Chemotherapy
11%
Prostate-specific Antigen Level
11%
Docetaxel Chemotherapy
11%
New Agents
11%
Duration of Therapy
11%
Pharmacodynamics
11%
Prostate-specific Antigen Response
11%
Nonsteroidal Antiandrogens
11%
R Statistical Software
11%
Withdrawal Interval
11%
Subsequent Therapy
11%
Total Prostate-specific Antigen
11%
Medicine and Dentistry
Antiandrogen
100%
Withdrawal Syndrome
100%
Enzalutamide
100%
Prostate Specific Antigen
44%
Castration Resistant Prostate Cancer
22%
Antiandrogen Therapy
22%
Oral Drug Administration
11%
Treatment Duration
11%
Pharmacodynamics
11%
Antigen Response
11%
Docetaxel
11%
Pharmacology, Toxicology and Pharmaceutical Science
Enzalutamide
100%
Withdrawal Syndrome
100%
Antiandrogen
100%
Prostate Specific Antigen
44%
Chemotherapy
22%
Castration Resistant Prostate Cancer
22%
Pharmacodynamics
11%
Docetaxel
11%
Taxane
11%
Oral Administration
11%
Neuroscience
Withdrawal Syndrome
100%
Antiandrogen
100%
Enzalutamide
100%
Prostate Specific Antigen
44%
Prostate
22%
Docetaxel
11%
Taxane
11%
Immunology and Microbiology
Prostate Specific Antigen
100%
Prostate
50%
Antigen Response
25%
Pharmacodynamics
25%